P
CNMD icon

Pitcairn’s CONMED CNMD Stock Holding History

Pitcairn’s Portfolio CNMD Stock Details CNMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,580
Closed -$447K – 589
2022
Q3 		$447K Buy
5,580
+2,329
+72% +$220K 0.05% 312
2022
Q2 		$311K Buy
3,251
+105
+3% +$12.6K 0.03% 425
2022
Q1 		$467K Sell
3,146
-92
-3% -$12.8K 0.04% 378
2021
Q4 		$459K Buy
3,238
+11
+0.3% +$1.56K 0.03% 397
2021
Q3 		$422K Buy
+3,227
New +$422K 0.03% 396
2020
Q1 		– Sell
-3,889
Closed -$434K – 459
2019
Q4 		$434K Buy
3,889
+787
+25% +$83.9K 0.04% 282
2019
Q3 		$298K Buy
3,102
+98
+3% +$9.2K 0.03% 383
2019
Q2 		$257K Buy
+3,004
New +$247K 0.03% 456

Other funds holding CNMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Pitcairn's CNMD Position: Q4 2022 in Review

Pitcairn sold out of CONMED (CNMD) in Q4 2022, closing a stake of 5,580 shares — an estimated $447K sold.

Pitcairn first reported a position in CNMD in Q2 2019 and held it in 8 quarters. The position peaked at $467K in Q1 2022. 238 funds tracked by Wall St. Rank hold CNMD as of Q4 2022.

  • Pitcairn reported no remaining CONMED position as of Q4 2022 after selling out during the quarter.
  • Pitcairn sold 5,580 CONMED shares in Q4 2022, an estimated $447K.
  • Pitcairn first reported a position in CONMED in Q2 2019 and held it in 8 quarters.
  • Pitcairn's CONMED position peaked at $467K in Q1 2022.
  • 238 funds tracked by Wall St. Rank held CONMED as of Q4 2022.

Based on Pitcairn's 13F filing for Q4 2022, filed 13 Feb 2023.